Morphometric studies in human pancreatic cancer argues against the etiological role of type 2 diabetes in pancreatic cancer

Histology and Histopathology

Volumn 25, Issue 4, 2010, Pages 423-432

  Saruc, Murat ^a   Iki, Katsumichi ^b   Pour, Parviz M ^b,c  

^a ACIBADEM UNIVERSITY   (Turkey)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Diabetes; IAPP; Morphometry; Pancreatic cancer; Pancreatic islets

Indexed keywords

AMYLIN; AMYLOID; GLUCAGON; INSULIN; PANCREAS POLYPEPTIDE; SOMATOSTATIN; TUMOR MARKER;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ARTICLE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MORPHOGENESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS; PANCREAS ISLET; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGY;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMYLOID; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; MORPHOGENESIS; PANCREAS; PANCREATIC NEOPLASMS; PANCREATIC POLYPEPTIDE; SOMATOSTATIN; TUMOR MARKERS, BIOLOGICAL;

EID: 77950234368     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Ahren B. and Andren-Sandberg A. (1993). Glucose tolerance and insulin secretion in experimental pancreatic cancer in the Syrianhamster. Res. Exp. Med. (Berl) 193, 21-26.
2. Ahren B. and Gutniak M. (1997). No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes. Eur. J. Endocrinol. 137, 643-649.
3. Ahren B., Simonsson E., Scheurink A.J., Mulder H., Myrsen U. and Sundler F (1997). Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 46, 97-106.
4. Andren-Sandberg A. (1996). Alteration of pancreatic hormones in human and experimental pancreatic cancer. Int. J. Pancreatol. Int. J. Pancreatol. 16.
5. Asano N., Manabe T., Imanishi K. and Tobe T. (1991). Changes of A, B and D cells in Langerhans islets in pancreatic cancers of hamsters. Nippon Geka. Hokan. 60, 233-242.
6. Basso D., Plebani M., Fogar P., Del Favero G., Briani G., Meggiato T., Panozzo M.P., Ferrara C., D'Angeli F. and Burlina A. (1994). Beta-cell function in pancreatic adenocarcinoma. Pancreas 9, 332-335.
7. Basso D., Greco E., Fogar P., Pucci P., Flagiello A., Baldo G., Giunco S., Valerio A., Navaglia F., Zambon C.F., Pedrazzoli S. and Plebani M. (2005). Pancreatic cancer-associated diabetes mellitus: an open field for proteomic applications. Clin. Chim. Acta 357, 184-189.
8. Basso D., Greco E., Fogar P., Pucci P., Flagiello A., Baldo G., Giunco S., Valerio A., Navaglia F., Zambon C.F., Falda A., Pedrazzoli S. and Plebani M. (2006). Pancreatic cancer-derived S-100A8 N-terminal peptide: A diabetes cause? Clin. Chim. Acta 372, 120-128.
9. Brand R.E., Ding X.Z., Young C.M. and Adrian T.E. (2002). The specificity of amylin for the diagnosis of pancreatic adenocarcinoma. Int. J. Gastrointest. Cancer 31, 123-128.
10. Cersosimo E., Pisters P.W., Pesola G., McDermott K., Bajorunas D. and Brennan M.F. (1991). Insulin secretion and action in patients with pancreatic cancer. Cancer 67, 486-493.
11. Chari S.T., Klee G.G., Miller L.J., Raimondo M. and DiMagno E.P. (2001). Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology 121, 640-645.
12. Ding X., Flatt P.R., Permert J. and Adrian T.E. (1998). Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin. Gastroenterology 114, 130-138.
13. Fogar P., Basso D., Panozzo M.P., Del Favero G., Briani G., Fabris C., D'Angeli F., Meggiato T., Ferrara C. and Plebani M. (1993). C-peptide pattern in patients with pancreatic cancer. Anticancer Res. 13, 2577-2580.
14. Frontoni S., Choi S.B., Banduch D. and Rossetti L (1991). In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle. Diabetes 40, 568-573.
15. Furnsinn C., Leuvenink H., Roden M., Nowotny P., Schneider B., Rohac M., Pieber T., Clodi M. and Waldhausl W. (1994). Islet amyloid polypeptide inhibits insulin secretion in conscious rats. Am. J. Physiol. 267, E300-305.
16. Hoppener J.W., Ahren B. and Lips C.J. (2000). Islet amyloid and type 2 diabetes mellitus. N. Engl. J. Med. 343, 411-419.
17. Iacobuzio-Donahue C.A., Ashfaq R., Maitra A., Adsay N.V., Shen-Ong G.L., Berg K., Hollingsworth M.A., Cameron J.L., Yeo C.J., Kern S.E., Goggins M., Hruban R.H. (2003). Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res. 63, 8614-8622.
18. In 't Veld P.A., Zhang F., Madsen O.D. and Kloppel G. (1992). Isletamyloid polypeptide immunoreactivity in the human fetal pancreas. Diabetologia 35, 272-276.
19. Koopmans S.J., van Mansfeld A.D., Jansz H.S., Krans H.M., Radder J.K., Frolich M., de Boer S.F., Kreutter D.K., Andrews G.C. and Maassen J.A. (1991). Amylin-induced in vivo insulin resistance in conscious rats: the liver is more sensitive to amylin than peripheral tissues. Diabetologia 34, 218-224.
20. Kreutter D.K., Orena S.J., Torchia A.J., Contillo L.G., Andrews G.C. and Stevenson R.W. (1993). Amylin and CGRP induce insulin resistance via a receptor distinct from cAMP-coupled CGRP receptor. Am. J. Physiol. 264, E606-613.
21. Leighton B. and Cooper G.J. (1988). Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 335, 632-635.
22. Madsen O.D., Nielsen J.H., Michelsen B., Westermark P., Betsholtz C., Nishi M. and Steiner D.F. (1991). Islet amyloid polypeptide and insulin expression are controlled differently in primary and transformed islet cells. Mol. Endocrinol. 5, 143-148.
23. Makimattila S., Hietaniemi K., Kiviluoto T., Timonen T. and Yki-Jarvinen H. (2001). In vivo glucose-stimulated amylin secretion is increased in nondiabetic patients with pancreatic cancer. Metabolism 50, 1036-1042.
24. Missiaglia E., Blaveri E., Terris B., Wang Y.H., Costello E., Neoptolemos J.P., Crnogorac-Jurcevic T. and Lemoine N.R. (2004). Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int. J. Cancer 112, 100-112.
25. Mulder H., Ahren B., Stridsberg M. and Sundler F. (1995). Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rats islets following dexamethasone treatment. Diabetologia 38, 395-402.
26. Mulder H., Ahren B. and Sundler F. (1996a). Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats. Diabetologia 39, 649-657.
27. Mulder H., Ahren B. and Sundler F. (1996b). Islet amyloid polypeptide and insulin gene expression are regulated in parallel by glucose in vivo in rats. Am. J. Physiol. 271, E1008-1014.
28. Mulder H., Martensson H., Sundler F. and Ahren B. (2000). Differential changes in islet amyloid polypeptide (amylin) and insulin mRNA expression after high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism 49, 1518-1522.
29. Permert J., Herrington M,. Kazakoff K., Pour P.M. and Adrian T.E. (2001). Early changes in islet hormone secretion in the hamster pancreatic cancer model. Teratog. Carcinog. Mutagen. 21, 59-67.
30. Permert J., Ihse I., Jorfeldt L., von Schenck H., Arnqvist H.J. and Larsson J. (1993). Pancreatic cancer is associated with impaired glucose metabolism. Eur. J. Surg. 159, 101-107.
31. Permert J., Larsson J., Westermark G.T., Herrington M.K., Christmanson L., Pour P.M., Westermark P. and Adrian T.E. (1994). Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl. J. Med. 330, 313-318.
32. Pour P.M., Kazakoff K. and Dulany K. (1994). A new technique for simultaneous demonstration of 4 tumor-associated antigens in pancreatic cancer cells. Zentralbl. Pathol. 140, 397-401.
33. Pour P.M., Schmied B.M., Ulrich A.B., Friess H., Andren-Sandberg A. and Buchler M.W. (2001). Abnormal differentiation of islet cells in pancreatic cancer. Pancreatology 1, 110-116.
34. Rosty C., Ueki T., Argani P., Jansen M., Yeo C.J., Cameron J.L., Hruban R.H. and Goggins M. (2002). Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. Am. J. Pathol. 160, 45-50.
35. Saito K., Yaginuma N. and Takahashi T. (1979). Differential volumetry of A, B and D cells in the pancreatic islets of diabetic and nondiabetic subjects. Tohoku. J. Exp. Med. 129, 273-283.
36. Schmied B.M., Ulrich A.B., Matsuzaki H., Li C., Friess H., Bochler M.W., Andren-Sandberg A., Adrian T.E. and Pour P.M. (2000). Alteration of the Langerhans islets in pancreatic cancer patients. Int. J. Pancreatol. 28, 187-197.
37. Schwarts S.S., Zeidler A., Moossa A.R., Kuku S.F. and Rubenstein A.H. (1978). A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Am. J. Dig. Dis. 23, 1107-1114.
38. Shen J., Person M.D., Zhu J., Abbruzzese J.L. and Li D. (2004). Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 64, 9018-9026.
39. Souza S.J.J., Machado, M.C.C., Fortes M.A.H.Z., Giorgi R.R., Cunha J.E.M. and Jukemura J. (2006). Cytokine-like FAM3D gene is associated to diabetes mellitus in pancreatic adenocarcinoma. Pancreas 33, 498
40. Stridsberg M., Eriksson B., Lundqvist G., Skogseid B., Wilander E. and Oberg K. (1995). Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours. Regul. Pept. 55, 119-131.
41. Verchere C.B., D'Alessio D.A., Prigeon R.L., Hull R.L. and Kahn S.E. (2000). The constitutive secretory pathway is a major route for islet amyloid polypeptide secretion in neonatal but not adult rat islet cells. Diabetes 49, 1477-1484.
42. Wagoner P.K., Chen C., Worley J.F., Dukes I.D. and Oxford G.S. (1993). Amylin modulates beta-cell glucose sensing via effects on stimulus-secretion coupling. Proc. Natl. Acad. Sci. USA 90, 9145-9149.
43. Wang F., Adrian T.E., Westermark G., Gasslander T. and Permert J. (1999a). Dissociated insulin and islet amyloid polypeptide secretion from isolated rat pancreatic islets cocultured with human pancreatic adenocarcinoma cells. Pancreas 18, 403-409.
44. Wang F., Adrian T.E., Westermark G.T., Ding X., Gasslander T. and Permert J. (1999b). Islet amyloid polypeptide tonally inhibits beta-, alpha-, and delta-cell secretion in isolated rat pancreatic islets. Am. J. Physiol. 276, E19-24.
45. Wang Z.L., Bennet W.M., Ghatei M.A., Byfield P.G., Smith D.M. and Bloom S.R. (1993). Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. Diabetes 42, 330-335.
46. Zervos E.E., Tanner S.M., Osborne D.A., Bloomston M., Rosemurgy A.S., Ellison E.C., Melvin W.S. and de la Chapelle A. (2006). Differential Gene Expression in Patients Genetically Predisposed to Pancreatic Cancer. J. Surg. Res. 135, 317-322.